7173-65-1

Basic information

• Product Name: N-methyldioleylamine
• Synonyms: N-Methyldioleylamine; (9E)-N-methyl-N-[(9E)-octadec-9-en-1-yl]octadec-9-en-1-amine
• CAS NO: 7173-65-1
• Molecular Formula: C₃₇H₇₃N
• Molecular Weight: 531.9822
• EINECS: 230-531-5
• Mol File: 7173-65-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 593.9°C at 760 mmHg
• Flash Point: 264.8°C
• Density: 0.839g/cm³
• Vapor Pressure: 4.49E-14mmHg at 25°C
• Refractive Index: 1.471
• CAS DataBase Reference: N-methyldioleylamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyldioleylamine(7173-65-1)
• EPA Substance Registry System: N-methyldioleylamine(7173-65-1)

Safety Data

• Hazardous Substances Data: 7173-65-1(Hazardous Substances Data)

Upstream product

• 35709-09-2 oleyl methanesulfonate 
• 22146-69-6 (Z)-N-methyloctadec-9-en-1-amine 

Relevant articles and documents

Simplifying the Chemical Structure of Cationic Lipids for siRNA-Lipid Nanoparticles

We report a potent cationic lipid, SST-02 ((3-hydroxylpropyl)dilinoleylamine), which possesses a simple chemical structure and is synthesized just in one step. Cationic lipids are key components of siRNA-lipid nanoparticles (LNP), which may serve as potential therapeutic agents for various diseases. For a decade, chemists have given enhanced potency and new functions to cationic lipids along with structural complexity. In this study, we conducted a medicinal chemistry campaign pursuing chemical simplicity and found that even dilinoleylmethylamine (SST-01) and methylpalmitoleylamine could be used for the in vitro and in vivo siRNA delivery. Further optimization revealed that a hydroxyl group boosted potency, and SST-02 showed an ID50 of 0.02 mg/kg in the factor VII (FVII) model. Rats administered with 3 mg/kg of SST-02 LNP did not show changes in body weight, blood chemistry, or hematological parameters, while the AST level decreased at a dose of 5 mg/kg. The use of SST-02 avoids a lengthy synthetic route and may thus decrease the future cost of nucleic acid therapeutics.

RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF KRAS GENE

The present invention provides a composition for suppressing the expression of a KRAS gene, comprising a lipid particle containing, as a drug, a double-stranded nucleic acid having an antisense strand having a sequence of bases complementary to the sequence of at least 19 continuous bases of any one KRAS gene's mRNA of sequence Nos. 1 to 3; and a cationic lipid represented by the following formula (I): wherein R1 and R2, which are the same or different, are each linear or branched alkyl, alkenyl or alkynyl having a carbon number of from 12 to 24; L1 and L2, which are the same or different, are each —CO—O— or —O—CO—; a and b, which are the same or different, are each 1 to 3; and R3 is a hydrogen atom, alkyl having a carbon number of from 1 to 6, or alkenyl having a carbon number of from 3 to 6, and the like.